Senescence and cellular ageing pathways.
Targeting senescent cells, telomere maintenance, and NAD+ availability.
Cellular senescence is a state in which a damaged cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete a mix of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, which is thought to drive chronic low-grade inflammation in surrounding tissue. Clearing these cells in animal models has been associated with improvements in several age-related measures, which is the entire premise behind senolytic compounds. One compound here exploits a specific vulnerability. In senescent cells the transcription factor FOXO4 accumulates and binds the tumour suppressor p53, holding it in the nucleus and preventing it from triggering apoptosis. That interaction is what keeps a damaged cell alive when it should have died. A retro-inverso peptide designed to disrupt the FOXO4 and p53 interface frees p53 to initiate intrinsic apoptotic signalling. Because healthy cells do not depend on this interaction for survival, the effect is proposed to be selective for senescent cells. A second approach targets telomere maintenance. Telomeres shorten with each cell division until a cell reaches its replicative limit, and telomerase is the enzyme that can extend them. A short peptide in this group has been reported in cultured human cells to induce telomerase expression and extend the number of divisions past that limit, with a secondary proposed action on pineal function and melatonin output. A third targets NAD+ availability by inhibiting the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. NAD+ is a substrate for sirtuins and a central currency of cellular energy metabolism, and its decline with age is a well-described observation. Honesty about this pathway is essential. Senescence biology is real and actively researched, and the molecular interactions described above have been characterised in cells and rodents. What is missing is human evidence. There are no controlled clinical trials demonstrating that any of these compounds slow ageing, extend healthy lifespan, or improve any clinical outcome in people. Deliberately inducing apoptosis or manipulating telomerase activity also carries theoretical risks that have not been characterised in humans, since telomerase reactivation is a feature of many cancers. None of these compounds is approved anywhere, and all are sold as unregulated research material.
Peptides acting through this pathway.
FAQ.
What does senescence and cellular ageing pathways do?
Cellular senescence is a state in which a damaged cell permanently stops dividing but does not die. Senescent cells accumulate with age and secrete a mix of inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype, which is thought to drive chronic low-grade inflammation in surrounding tissue. Clearing these cells in animal models has been associated with improvements in several age-related measures, which is the entire premise behind senolytic compounds. One compound here exploits a specific vulnerability. In senescent cells the transcription factor FOXO4 accumulates and binds the tumour suppressor p53, holding it in the nucleus and preventing it from triggering apoptosis. That interaction is what keeps a damaged cell alive when it should have died. A retro-inverso peptide designed to disrupt the FOXO4 and p53 interface frees p53 to initiate intrinsic apoptotic signalling. Because healthy cells do not depend on this interaction for survival, the effect is proposed to be selective for senescent cells. A second approach targets telomere maintenance. Telomeres shorten with each cell division until a cell reaches its replicative limit, and telomerase is the enzyme that can extend them. A short peptide in this group has been reported in cultured human cells to induce telomerase expression and extend the number of divisions past that limit, with a secondary proposed action on pineal function and melatonin output. A third targets NAD+ availability by inhibiting the enzyme that methylates nicotinamide and diverts it away from NAD+ salvage. NAD+ is a substrate for sirtuins and a central currency of cellular energy metabolism, and its decline with age is a well-described observation. Honesty about this pathway is essential. Senescence biology is real and actively researched, and the molecular interactions described above have been characterised in cells and rodents. What is missing is human evidence. There are no controlled clinical trials demonstrating that any of these compounds slow ageing, extend healthy lifespan, or improve any clinical outcome in people. Deliberately inducing apoptosis or manipulating telomerase activity also carries theoretical risks that have not been characterised in humans, since telomerase reactivation is a feature of many cancers. None of these compounds is approved anywhere, and all are sold as unregulated research material.
Which peptides act through senescence and cellular ageing pathways?
FOXO4-DRI, Epitalon, 5-Amino-1MQ. They share this pathway but differ in evidence, approval, and safety.
Does this mechanism prove a peptide works?
No. Mechanistic plausibility is not proof of clinical benefit. A plausible pathway is a reason to study a compound, not evidence that it works in humans.